Prevention of stroke: a global perspective

JD Pandian, SL Gall, MP Kate, GS Silva, RO Akinyemi… - The Lancet, 2018 - thelancet.com
Along with the rising global burden of disability attributed to stroke, costs of stroke care are
rising, providing the impetus to direct our research focus towards effective measures of …

The burden of cardiovascular disease in low-and middle-income countries: epidemiology and management

ADK Bowry, J Lewey, SB Dugani… - Canadian Journal of …, 2015 - Elsevier
Cardiovascular disease (CVD) is the second leading cause of mortality worldwide,
accounting for 17 million deaths in 2013. More than 80% of these cases were in low-and …

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

G Roshandel, M Khoshnia, H Poustchi, K Hemming… - The Lancet, 2019 - thelancet.com
Background A fixed-dose combination therapy (polypill strategy) has been proposed as an
approach to reduce the burden of cardiovascular disease, especially in low-income and …

Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications

AJ Cross, RA Elliott, K Petrie… - Cochrane Database …, 2020 - cochranelibrary.com
Background Older people taking multiple medications represent a large and growing
proportion of the population. Managing multiple medications can be challenging, and this is …

The PERSIAN cohort: providing the evidence needed for healthcare reform

S Eghtesad, Z Mohammadi, A Shayanrad… - Archives of Iranian …, 2017 - journalaim.com
In the past, communicable diseases caused the highest mortality in Iran. Improvements in
socioeconomic status and living standards including access to safe drinking water, along …

Chronic disease research in Europe and the need for integrated population cohorts

P Brennan, M Perola, GJ van Ommen, E Riboli… - European journal of …, 2017 - Springer
The burden of chronic disease in Europe is characterized by several positive trends, but also
some major new challenges. On one hand there has been an important and consistent …

Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases

E Bahiru, AN De Cates, MRB Farr… - Cochrane Database …, 2017 - cochranelibrary.com
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death
and disability worldwide, yet ASCVD risk factor control and secondary prevention rates …

Uses of polypills for cardiovascular disease and evidence to date

MD Huffman, D Xavier, P Perel - The Lancet, 2017 - thelancet.com
Polypills have been approved in more than 30 countries, but worldwide experience with and
availability of polypills remain limited, unlike fixed-dose combinations in other diseases such …

Strengths and limitations of using the polypill in cardiovascular prevention

A Roy, N Naik, K Srinath Reddy - Current cardiology reports, 2017 - Springer
Abstract Purpose of Review Polypill and its role in cardiovascular disease (CVD) prevention
has been extensively discussed and debated since the inception of the concept in 2003 …

Fixed-dose combination (polypill) for cardiovascular disease prevention: a meta-analysis

AI Abushouk, A Sayed, M Munir, E Ghanem… - American journal of …, 2022 - Elsevier
Introduction This meta-analysis was performed to assess the efficacy of fixed-dose
combination (polypill) in reducing the risk of mortality and cardiovascular events. Methods …